These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 20425417)

  • 21. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
    Carter BZ; Mak PY; Mu H; Zhou H; Mak DH; Schober W; Leverson JD; Zhang B; Bhatia R; Huang X; Cortes J; Kantarjian H; Konopleva M; Andreeff M
    Sci Transl Med; 2016 Sep; 8(355):355ra117. PubMed ID: 27605552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia.
    Chen Y; Peng C; Sullivan C; Li D; Li S
    Anticancer Agents Med Chem; 2010 Feb; 10(2):111-5. PubMed ID: 20184539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting chronic myeloid leukemia stem cells.
    Helgason GV; Young GA; Holyoake TL
    Curr Hematol Malig Rep; 2010 Apr; 5(2):81-7. PubMed ID: 20425400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
    Wisniewski D; Lambek CL; Liu C; Strife A; Veach DR; Nagar B; Young MA; Schindler T; Bornmann WG; Bertino JR; Kuriyan J; Clarkson B
    Cancer Res; 2002 Aug; 62(15):4244-55. PubMed ID: 12154026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel combination treatments targeting chronic myeloid leukemia stem cells.
    Al Baghdadi T; Abonour R; Boswell HS
    Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):94-105. PubMed ID: 22178144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic myeloid leukemia stem cells.
    Houshmand M; Simonetti G; Circosta P; Gaidano V; Cignetti A; Martinelli G; Saglio G; Gale RP
    Leukemia; 2019 Jul; 33(7):1543-1556. PubMed ID: 31127148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
    Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C
    Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular pathways to CML stem cells.
    Rice KN; Jamieson CH
    Int J Hematol; 2010 Jun; 91(5):748-52. PubMed ID: 20533007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In search of CML stem cells' deadly weakness.
    Pellicano F; Sinclair A; Holyoake TL
    Curr Hematol Malig Rep; 2011 Jun; 6(2):82-7. PubMed ID: 21373837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S; Holtz M; Gupta M; Bhatia R
    Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hurdles toward a cure for CML: the CML stem cell.
    Gallipoli P; Abraham SA; Holyoake TL
    Hematol Oncol Clin North Am; 2011 Oct; 25(5):951-66, v. PubMed ID: 22054728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.
    Casetti L; Martin-Lannerée S; Najjar I; Plo I; Augé S; Roy L; Chomel JC; Lauret E; Turhan AG; Dusanter-Fourt I
    Cancer Res; 2013 Apr; 73(7):2052-8. PubMed ID: 23400594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia.
    Valent P; Deininger M
    Leuk Lymphoma; 2008 Apr; 49(4):604-9. PubMed ID: 18398718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells.
    Moore S; Haylock DN; Lévesque JP; McDiarmid LA; Samels LM; To LB; Simmons PJ; Hughes TP
    Blood; 1998 Oct; 92(7):2461-70. PubMed ID: 9746786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R; Munthe HA; Verfaillie CM
    Exp Hematol; 1999 Sep; 27(9):1384-96. PubMed ID: 10480429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The challenges of targeting chronic myeloid leukemia stem cells.
    Jiang X; Smith C; Eaves A; Eaves C
    Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 2():S71-80. PubMed ID: 17382016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.